← Back to Search

PI3K Inhibitor

A Study of INCB059872 in Relapsed or Refractory Ewing Sarcoma

Phase 1
Waitlist Available
Research Sponsored by Incyte Corporation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to approximately 6 months.
Awards & highlights
No Placebo-Only Group

Summary

The purpose of this study is to evaluate the safety and preliminary antitumor activity of INCB059872 in participants with Ewing sarcoma who are refractory or relapsed from prior standard therapy and not eligible for further standard systemic therapy.

Eligible Conditions
  • Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to approximately 6 months.
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to approximately 6 months. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of adverse events
Secondary study objectives
Cl/F of INCB059872
Cmax of INCB059872
Objective response rate
+2 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: INCB059872Experimental Treatment1 Intervention
INCB059872

Find a Location

Who is running the clinical trial?

Incyte CorporationLead Sponsor
393 Previous Clinical Trials
63,819 Total Patients Enrolled
Fred Zheng, MDStudy DirectorIncyte Corporation
5 Previous Clinical Trials
467 Total Patients Enrolled
~3 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top